192
Participants
Start Date
July 24, 2015
Primary Completion Date
January 22, 2021
Study Completion Date
March 7, 2023
Oleclumab
Participants will receive IV infusion of oleclumab as stated in arms' description.
Durvalumab
Participants will receive IV infusion of durvalumab as stated in arms' description.
Research Site, Camperdown
Research Site, St Leonards
Research Site, Parkville
Research Site, Woolloongabba
Research Site, Durham
Research Site, Atlanta
Research Site, Gainesville
Research Site, Nashville
Research Site, Columbus
Research Site, Cincinnati
Research Site, St Louis
Research Site, Dallas
Research Site, Houston
Research Site, La Jolla
Research Site, New Haven
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Lead Sponsor
MedImmune LLC
INDUSTRY